AxoGen, Inc. Aktie News

Leading individual contributors to the Fund's relative performance included Axogen, Inc., a holding within the health-care equipment industry. A provider of prepared food items such as meatballs and paninis, Mama's targets the deli area of grocery stores and warehouse clubs. On the downside, software distribution company Climb Global Solutions, Inc. was the Fund's leading laggard in the quarter.

ALACHUA, Fla. and TAMPA, Fla.

ALACHUA, Fla. and TAMPA, Fla.

Axogen, Inc. (AXGN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Axogen's CEO sold 25,000 shares directly for $750,000 on Dec. 10, 2025. The sale represented 28.24% of the CEO's direct holdings prior to the transaction, reducing direct ownership to 63,537 shares (approximately 0.14% of shares outstanding).

ALACHUA, Fla. and TAMPA, Fla., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced preliminary unaudited fourth quarter and full-year 2025 key financials.

ALACHUA, Fla. and TAMPA, Fla., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical technologies for the restoration of peripheral nerve function, today announced that the U.S. Food and Drug Administration (the “FDA”) has approved the Biologics License Application (“BLA”) for AVANCE® (acellular nerve allograft-arwx).

The U.S. Food and Drug Administration has approved Axogen's nerve repair graft, the health regulator said on Wednesday.